

# Heart failure guidelines

## A concise summary for the GP

**JOHN J. ATHERTON** PhD, MB BS, FRACP, FCSANZ, FESC

**RALPH AUDEHM** MB BS, DipRACOG; **CIA CONNELL** BPharm, MClinPharm

Guidelines have recently been released by the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand on the prevention, detection and management of heart failure in Australia. This article provides a brief and practical summary of the guidelines, focusing on their application to diagnosis and management of heart failure in general practice.

**T**he National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand have recently released *Guidelines for the prevention, detection and management of heart failure in Australia 2018*.<sup>1,2</sup> This article provides a concise and practical

synopsis of the guidelines, with a focus on their application to diagnosis and management of patients with heart failure (HF) in general practice.

### What is heart failure?

HF is a clinical syndrome with symptoms (usually dyspnoea) and signs secondary to an abnormality of cardiac structure or function that impairs the ability of the heart to fill with blood at normal pressure or eject blood sufficient to fulfil the needs of the metabolising organs. Once a clinical diagnosis of HF is made, it is generally classified according to the left ventricular ejection fraction (LVEF), into either HF associated with a reduced LVEF below 50% (HFrEF) or HF associated with a preserved LVEF of 50% or higher (HFpEF). This distinction is usually made with echocardiography. In patients with HFpEF or in those with HFrEF associated with only a mildly reduced LVEF (41 to 49%), additional diagnostic criteria are required (Box 1).

**Medicine** Today 2019; 20(6): 14-24


Associate Professor Atherton is Director of Cardiology at the Royal Brisbane and Women's Hospital, Brisbane; Associate Professor in Medicine at the University of Queensland; Adjunct Professor at Queensland University of Technology, Brisbane; and Professor of Cardiology and Heart Failure Management at the University of the Sunshine Coast, Sunshine Coast, Qld. Associate Professor Audehm is a General Practitioner, Department of General Practice at the University of Melbourne, Melbourne. Ms Connell is Clinical Manager at the National Heart Foundation of Australia; and Senior Clinical Pharmacist specialising in cardiology at Alfred Hospital, Melbourne, Vic.



### Epidemiology of heart failure

HF affects over 38 million people worldwide and it is estimated that about 480,000 people in Australia are affected.<sup>3,4</sup> HF is more common in the elderly, and the age-standardised prevalence of HF is 1.7-fold higher in Indigenous Australians compared with non-Indigenous Australians.<sup>5</sup> The prevalence of HF is increasing at least in part due to the ageing population and better survival in patients with cardiovascular disease. Patients with HF experience repeated hospitalisations with

© LARABELOVA/ISTOCKPHOTO.COM  
MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY



## KEY POINTS

- Heart failure (HF) is generally categorised as HF associated with a reduced left ventricular ejection fraction (LVEF) below 50% (HFrEF) or HF associated with a preserved LVEF of 50% or higher (HFpEF).
- Echocardiography is the single most useful investigation in patients with suspected HF. If not available in a timely fashion, measurement of plasma B-type natriuretic peptide (BNP) or N-terminal pro-BNP levels improves diagnostic accuracy.
- ACE inhibitors (or angiotensin receptor blockers [ARBs]), beta blockers and low-dose mineralocorticoid receptor antagonists (MRAs) improve survival and decrease hospitalisation in patients with HFrEF.
- The ACE inhibitor (or ARB) should be changed to an angiotensin receptor neprilysin inhibitor (unless contraindicated or not tolerated) for patients with HFrEF associated with an LVEF of 40% or less despite initial medical management.
- Ivabradine should be considered for patients with HFrEF associated with an LVEF of 35% or less and a sinus rate of 70 beats/min or greater despite standard medical management (including a beta blocker unless contraindicated).
- Referral for implantable cardioverter defibrillators and/or cardiac resynchronisation therapy should be considered for patients with persistent HFrEF associated with an LVEF of 35% or less despite optimal medical therapy.
- Low-dose MRAs may be considered to decrease HF hospitalisation in patients with HFpEF.
- Multidisciplinary HF disease management, nurse-led medication titration and exercise training have been shown to improve outcomes in patients with HF.
- Comorbidities should be identified and managed in all patients with HF.
- Referral to palliative care services should be considered in patients with advanced HF.

## Approach to diagnosis and monitoring of heart failure

HF is a clinical diagnosis that may be made following the initial history taking, physical examination and chest x-ray (Flowchart 1). Further initial investigations including a 12-lead electrocardiogram, blood biochemistry and full blood count should be performed to assess comorbidities and identify alternative causes of fluid overload. The echocardiogram is the single most useful investigation in patients with suspected HF. It improves diagnostic accuracy and provides additional structural and functional information (including measurement of LVEF and assessment of valvular function) to guide management. However, if the diagnosis is unclear and an echocardiogram cannot be arranged in a timely fashion, then measurement of plasma B-type natriuretic peptide (BNP) or N-terminal pro-BNP levels improves diagnostic accuracy.<sup>20</sup>

overall survival worse than most non-haematological malignancies.<sup>6,7</sup>

### Heart failure prevention

Although largely based on observational studies, smoking cessation, avoidance of excess alcohol, weight reduction (if overweight or obese) and regular physical activity are all strongly recommended to decrease the risk of developing HF.<sup>8-13</sup> Pharmacological interventions that have been shown to decrease the risk of developing HF in large-scale, randomised controlled

trials include use of blood pressure-lowering and lipid-lowering therapies, according to published guidelines, ACE inhibitors in patients with cardiovascular disease, and sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes associated with cardiovascular disease and insufficient glycaemic control despite first-line glucose-lowering therapy (usually metformin).<sup>14-17</sup> ACE inhibitors and beta blockers are also strongly recommended in patients with asymptomatic left ventricular systolic dysfunction.<sup>18,19</sup>

**1. HEART FAILURE DIAGNOSTIC CRITERIA****HFrEF**

- Symptoms with or without signs of heart failure and
- LVEF <50%\*

**HFpEF**

- Symptoms with or without signs of heart failure and
- LVEF ≥50%
- and
- Objective evidence of:
  - relevant structural heart disease (LV hypertrophy, left atrial enlargement)
- and/or
- diastolic dysfunction, with high filling pressure demonstrated by any of the following: invasive means (cardiac catheterisation), echocardiography, biomarker testing (elevated BNP or NT-proBNP levels), exercise testing (invasive or echocardiography)

\* If LVEF mildly reduced (LVEF 41 to 49%), additional criteria required (e.g. signs of heart failure, diastolic dysfunction with high filling pressure demonstrated by invasive means, echocardiography or biomarker testing).

Abbreviations: BNP = B-type natriuretic peptide; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LV = left ventricular; LVEF = left ventricular ejection fraction; NT = N-terminal.

Further evaluation to determine the aetiology of HF is important. The need for specific imaging investigations to diagnose coronary artery disease such as invasive coronary angiography, CT coronary angiography, cardiac magnetic resonance imaging or stress imaging will be determined by the presence or absence of angina and the pre-test probability of coronary artery disease. Cardiac magnetic resonance imaging, positron emission tomography or bone scintigraphy may be performed in patients with HF associated with unexplained increased left ventricular wall thickness to diagnose inflammatory or infiltrative cardiomyopathies.

Clinical evaluation to identify symptoms or signs of congestion, serum

biochemistry, full blood count and 12-lead electrocardiography should be performed regularly (six to 12 monthly once stabilised) and if there is a change in clinical status. The echocardiogram is usually repeated three to six months after commencing medical therapy in patients with HFrEF to guide further management, including the need for device therapy.

**Management of acute heart failure**

The management of acute HF should be guided by the patient's vital signs, oxygen saturation and the presence or absence of congestion and hypoperfusion. Management includes use of intravenous diuretics in most patients accompanied by the selected use of oxygen therapy (if hypoxaemic), positive pressure ventilation, vasodilators and inotropes.<sup>2</sup>

**Management of heart failure associated with a reduced LVEF**

Several medical and device-related therapeutic interventions have been shown to improve survival, decrease HF hospitalisation and improve symptoms and quality of life in patients with HFrEF (Flowchart 2).

**Initial medical management**

ACE inhibitors, beta blockers and low-dose mineralocorticoid receptor antagonists (MRAs) have all been shown to improve survival and decrease hospitalisation in patients with HFrEF associated with a moderate or severe reduction in LVEF.<sup>21-27</sup> These treatments are therefore strongly recommended in all patients with HFrEF associated with an LVEF of 40% or less unless contraindicated or not tolerated; and may also be considered in patients with HFrEF associated with an LVEF of 41 to 49%.<sup>28-30</sup>

An ACE inhibitor (or angiotensin receptor blocker [ARB] if an ACE inhibitor is contraindicated or not tolerated) is usually started initially (often in combination with a loop diuretic to manage congestion). A beta blocker (specifically bisoprolol, carvedilol, metoprolol controlled release or extended release, or nebivolol) is then added


once the patient is stabilised with no or minimal clinical congestion on physical examination, either before or after the MRA (low-dose spironolactone or eplerenone 25 to 50 mg daily; Flowchart 2). These treatments are started at low doses and gradually uptitrated (usually doubled every two to four weeks) aiming for target doses.<sup>31</sup> However, uptitration should not be to the detriment of starting other drugs that have been shown to decrease mortality in patients with HFrEF, with the aim to have the patient on a combination of all three classes of medical therapy, even if only low doses are able to be achieved.

**Medications used in selected patients**

Loop diuretics are favoured to manage congestion and are usually started at low doses, such as 20 to 40 mg furosemide orally daily.<sup>32</sup> Ongoing monitoring of fluid status, electrolytes and renal function is important and the diuretic dose adjusted according to clinical response. Patients may also be educated to adjust the diuretic dose according to their symptoms and daily weight measurements. Thiazides or thiazide-like diuretics may be added to loop diuretics in patients with refractory congestion; however, close monitoring of electrolytes and renal function is required.

In patients with HFrEF associated with an LVEF of 40% or less despite initial medical management, the ACE inhibitor (or ARB) should be changed to a low or moderate dose of an angiotensin receptor neprilysin inhibitor (ARNI) (unless contraindicated or not tolerated) and gradually uptitrated every two to four weeks aiming for the target dose (see Flowchart 2).<sup>31</sup> This recommendation is based on the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF) in which the ARNI (sacubitril-valsartan) was shown to improve survival and decrease hospitalisation compared with an ACE inhibitor (enalapril) in such patients.<sup>33</sup> In view of an increased risk of angioedema, concomitant use of ACE inhibitors and ARNIs is contraindicated,

**1. DIAGNOSTIC WORK UP AND MANAGEMENT OF SUSPECTED HEART FAILURE**



Abbreviations: ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BNP = B-type natriuretic peptide; CXR = chest x-ray; ECG = electrocardiogram; EUC = electrolytes, urea, creatinine; FBC = full blood count; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LFT = liver function tests; MRA = mineralocorticoid receptor antagonist; NT-proBNP = N-terminal prohormone of B-type natriuretic peptide.


and at least a 36-hour washout period should be allowed when switching therapy. ARNIs are generally well tolerated, but are associated with a higher incidence of hypotension, so are generally avoided or used cautiously if the systolic blood pressure is persistently below 100 mmHg.

Ivabradine should also be considered in patients with persistent HFrEF associated with an LVEF of 35% or less and a sinus rate of 70 beats/min or higher despite standard medical management (including a maximally tolerated or target dose of a

beta blocker unless contraindicated); however, the approved indication of ivabradine in Australia requires a sinus rate of 77 beats/min or higher (Flowchart 2). This recommendation is based on the Systolic Heart failure treatment with the I<sub>f</sub> Inhibitor Ivabradine Trial (SHIFT), in which ivabradine reduced cardiovascular mortality and HF hospitalisation, with greater benefit observed in patients with faster sinus rates.<sup>34</sup> Ivabradine is a sinus node inhibitor and should therefore only be used in patients in sinus rhythm.

Additional treatment options used in very selected patients include hydralazine plus nitrates, N-3 polyunsaturated fatty acids and low-dose digoxin (aiming for serum digoxin levels of 0.5 to 0.9 ng/mL).<sup>35-39</sup>

Unless a reversible cause of HFrEF has been identified and corrected, neuro-hormonal modulators (ACE inhibitors, ARBs, ARNIs, beta blockers, MRAs) should be continued long-term even if the LVEF improves, to decrease the risk of recurrence.<sup>40,41</sup>



### When to consider cardiac electronic device therapy

Implantable cardioverter defibrillators to treat malignant ventricular arrhythmias and cardiac resynchronisation therapy to allow biventricular pacing to resynchronise ventricular contraction in patients with a broad QRS (130 ms or more) have been shown to improve outcomes in selected patients with persistent HFrEF associated with a moderate or severe

reduction in LVEF (LVEF of 35% or less) despite optimal medical therapy.<sup>42-45</sup> Such patients should be reviewed by a cardiologist to consider whether these treatments should be offered.

### Surgical and percutaneous management of coronary artery disease and valvular heart disease

Patient selection and procedural planning for the surgical or percutaneous

management of coronary artery disease and valvular heart disease in patients with HF is guided by a multidisciplinary heart team. The long-term clinical benefits need to be balanced against the short-term morbidity and mortality associated with these procedures, with additional considerations including the presence of associated comorbidities and patient frailty. Coronary artery bypass surgery or percutaneous coronary intervention may be undertaken in patients with haemodynamically significant coronary artery stenoses, even if associated with a moderate or severe reduction in LVEF (LVEF of 35% or less), with the evidence for improved clinical outcomes being strongest for coronary artery bypass surgery.<sup>46</sup>

Surgical aortic valve replacement is recommended in patients with HF associated with either severe aortic stenosis or severe aortic regurgitation in the absence of major comorbidity or frailty to improve symptoms and survival.<sup>47</sup> Alternatively, transcatheter aortic valve implantation may be undertaken in selected patients with HF and severe aortic stenosis who are considered inoperable or at intermediate to high risk of operative mortality for surgical aortic valve replacement.<sup>48-51</sup> Surgical mitral valve repair or replacement may be undertaken in patients with HF associated with moderate-to-severe mitral regurgitation at the time of elective coronary artery bypass surgery.<sup>52</sup> The role of surgical or percutaneous mitral valve repair or replacement in patients with HF associated with severe functional mitral regurgitation despite optimal medical and device therapy is evolving.<sup>53,54</sup>

### Ventricular assist device therapy and heart transplantation

Patients with intractable, severe HF despite optimal medical therapy and pacemaker therapy (if indicated) have a particularly poor prognosis. In the absence of major comorbidities, such patients should be referred to specialist HF centres, to consider further treatment options including ventricular assist device therapy and heart transplantation.<sup>55,56</sup>

### Management of heart failure associated with a preserved LVEF

According to registry studies, HFpEF accounts for about one-half of all cases of HF.<sup>57</sup> These patients are usually elderly with multiple comorbidities. In contrast to the rich evidence-base in HFrEF, none of the large-scale randomised controlled trials conducted to date in patients with HFpEF have achieved their primary endpoint.<sup>58-61</sup> However, there have been reductions in HF hospitalisation observed in some studies evaluating MRAs and ARBs.<sup>58,61</sup> Loop diuretics are usually required to manage congestion (although thiazide or thiazide-like diuretics may be preferred in patients with predominant hypertension). Comorbidities, including hypertension, ischaemic heart disease, diabetes and atrial fibrillation, should be identified and managed. Low-dose MRAs may be considered to decrease HF hospitalisation.<sup>61</sup>

### Models of care to improve evidence-based practice

The most vulnerable period for patients with HF is within the first few weeks following discharge from hospital. These patients should be reviewed within one to two weeks, regardless of the type of appointment, to review and uptitrate medication. Patient and carer education about HF and self-management should be commenced soon after diagnosis, with ongoing revision. Several nonpharmacological strategies have been shown to improve evidence-based practice and patient outcomes in patients with HF, including multidisciplinary HF disease management, nurse-led medication titration and exercise training.


### Multidisciplinary heart failure disease management

Multidisciplinary HF disease management refers to several interventions

delivered by HF nurses in collaboration with cardiologists or specialist physicians, GPs, pharmacists, physiotherapists, occupational therapists, exercise physiologists, dietitians, psychologists and palliative care physicians, as appropriate. These models of care have been shown to improve survival and decrease rehospitalisations, especially in high-risk patients such as those recently admitted to hospital with HF.<sup>62</sup> Although the evidence is strongest for face-to-face visits (either at home or in a clinic setting), if access to such care is limited, multidisciplinary telemonitoring or telephone-support programs have also been shown to improve outcomes.<sup>63,64</sup>

### Nurse-led medication titration

Numerous registries have reported under-dosing of evidenced-based treatment in HF. Nurse-led medication titration has been shown to increase the



## Come with **Cardiology Today** to PARIS!

Highlights from an Australian perspective:  
**ESC Congress Paris 2019** together with  
**World Congress of Cardiology.**

Spotlight: **Global cardiovascular health.**

SIGN UP FOR VIDEO HIGHLIGHTS VIA EMAIL:  
[CARDIOLOGYTODAY.COM.AU/ESC2019](http://CARDIOLOGYTODAY.COM.AU/ESC2019)

# Cardiology **Today**

PEER REVIEWED UPDATES FOR MEDICAL PRACTITIONERS

**TABLE. APPROACH TO MANAGING COMORBIDITIES IN PATIENTS WITH HEART FAILURE**

Comorbidity	Management
Hypertension	<ul style="list-style-type: none"> <li>An ACE inhibitor, ARB or ARNI; and a beta blocker and an MRA are recommended in patients with HFrEF.</li> <li>Avoid diltiazem, verapamil and moxonidine in patients with HFrEF.</li> <li>Optimal control of blood pressure is important in patients with HFpEF: an MRA with or without an ACE inhibitor or ARB are preferred.</li> </ul>
Coronary artery disease	<ul style="list-style-type: none"> <li>Beta blockers are recommended in patients with HFrEF.</li> <li>Consider ivabradine if sinus rate is 70 beats/min or above* and LVEF is 35% or less despite maximally tolerated doses of beta blockers.</li> <li>Avoid diltiazem, verapamil, moxonidine in patients with HFrEF.</li> <li>Revascularisation may improve symptoms and health outcomes.</li> </ul>
Atrial fibrillation	<ul style="list-style-type: none"> <li>Identify and treat reversible causes of AF.</li> <li>Determine risk of stroke to guide need for anticoagulation.</li> <li>Beta blockers and digoxin are favoured for ventricular rate control.</li> <li>Amiodarone may facilitate attainment/maintenance of sinus rhythm.</li> <li>Consider catheter ablation for recurrent, symptomatic AF (particularly with newly diagnosed or worsening HFrEF).</li> </ul>
Diabetes mellitus	<ul style="list-style-type: none"> <li>Aim for moderate glycaemic targets (HbA<sub>1c</sub> 7.1 to 8.0%).</li> <li>Metformin is usually first-line therapy.</li> <li>SGLT-2 inhibitors are usually second-line therapy (especially if underlying CVD).</li> <li>Avoid thiazolidinediones due to the risk of worsening HF.</li> </ul>
Chronic kidney disease, hyperkalaemia and hypokalaemia	<ul style="list-style-type: none"> <li>Exclude reversible causes of worsening renal function (volume status, nephrotoxic drugs, renovascular disease, urinary outflow obstruction).</li> <li>Temporarily cease renin-angiotensin-aldosterone inhibitors if acute hyperkalaemia occurs (potassium &gt;6 mmol/L).</li> <li>Consider dietary review and potassium binders for hyperkalaemia.</li> </ul>
Hyponatraemia	<ul style="list-style-type: none"> <li>Restrict fluid (unless hypovolaemic).</li> <li>Reconsider need for diuretics (unless congested).</li> <li>Consider AVP receptor antagonists for resistant hyponatraemia (serum sodium level below 130 mmol/L, unless hypovolaemic).</li> </ul>
Obesity	<ul style="list-style-type: none"> <li>Consider weight loss for severe obesity (BMI &gt;35 kg/m<sup>2</sup>).</li> </ul>
COPD/asthma	<ul style="list-style-type: none"> <li>Beta blockers are safe in most patients with COPD.</li> <li>Asthma is a relative contraindication to beta blockers: favour cardioselective beta blockers.</li> <li>Inhaled antimuscarinic agents are preferred over beta-2 agonists.</li> <li>Minimise doses of oral corticosteroids (inhaled corticosteroids are preferred).</li> <li>Avoid theophylline.</li> </ul>
Sleep disordered breathing	<ul style="list-style-type: none"> <li>Consider positive pressure ventilation for symptom relief for patients with predominant obstructive sleep apnoea.</li> <li>Optimise HF management and avoid adaptive servoventilation due to increased mortality in patients with predominant central sleep apnoea.</li> </ul>
Gout	<ul style="list-style-type: none"> <li>Consider colchicine, intra-articular steroids (unless anticoagulated) and brief oral corticosteroids for acute gout management. Then use allopurinol (or febuxostat if intolerant) coupled with dietary measures for gout prevention.</li> </ul>
Arthritis	<ul style="list-style-type: none"> <li>Avoid NSAIDs (or use cautiously) if severely decreased LVEF or hyponatraemia.</li> <li>Use TNF inhibitors cautiously and only if HF symptoms are well controlled.</li> </ul>
Depression	<ul style="list-style-type: none"> <li>Consider screening using PHQ-9 (or initial screen with PHQ-2).</li> <li>Consider cognitive behaviour therapy, pharmacological therapy (SSRIs preferred) and exercise training.</li> </ul>
Anaemia	<ul style="list-style-type: none"> <li>Anaemia = Hb &lt;120 g/L in women, Hb &lt;130 g/L in men.</li> <li>Identify and treat reversible causes (e.g. blood loss, iron, vitamin B<sub>12</sub> or folic acid deficiency).</li> <li>Erythropoietin should not be used routinely to treat anaemia, because of an increased risk of thromboembolic adverse events.</li> </ul>
Iron deficiency	<ul style="list-style-type: none"> <li>Consider measuring iron studies and full blood count in patients with persistent HFrEF and administering intravenous iron if iron deficient (iron deficiency = serum ferritin &lt;100 mg/L or 100 to 300 mg/L with transferrin saturation &lt;20%).</li> <li>Consider investigation for gastrointestinal pathology (especially if anaemic).</li> </ul>

\* Therapeutic Goods Administration Australia indication for ivabradine requires a sinus rate of 77 beats/min or more.

Abbreviations: ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; AVP = arginine vasopressin; BMI = body mass index; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease; Hb = haemoglobin; HF = heart failure; HFrEF = heart failure associated with a reduced left ventricular ejection fraction; HFpEF = heart failure associated with a preserved left ventricular ejection fraction; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; PHQ = Patient Health Questionnaire; SGLT = sodium-glucose cotransporter; SSRIs = selective serotonin reuptake inhibitors; TNF = tumour necrosis factor.

## 2. SUGGESTED QUALITY OF CARE MEASURES FOR PATIENTS WITH HEART FAILURE

### Newly diagnosed HF

- What proportion have had an ECG?
- What proportion have had an echocardiogram?

### All patients with HF

- What proportion have had an ECG within 12 months?
- What proportion have had an echocardiogram within two years?
- What proportion have an advanced healthcare directive?
- What proportion have been screened for depression?
- What proportion have had a care plan and care plan review?
- What proportion have had a home medication review?

### HF with a reduced LVEF (HFrEF)

- What proportion receive a prescription for an ACE inhibitor, ARB or ARNI?
- What proportion receive a prescription for a beta blocker?
- What proportion receive a prescription for an MRA?
- What proportion have achieved the target or maximum tolerated dose of an ACE inhibitor, ARB or ARNI by 6 months following commencement?
- What proportion have achieved the target or maximum tolerated dose of a beta blocker by 6 months following commencement?
- What proportion with an LVEF of 35% or less despite medical therapy have been referred for consideration of cardiac resynchronisation or implantable cardioverter defibrillator therapy?

### Atrial fibrillation

- What proportion receive a prescription for an anticoagulant?

### Following HF hospitalisation

- What proportion have been reviewed within 2 weeks?
- What proportion have a written discharge summary and HF action plan?
- What proportion have been referred to a multidisciplinary HF disease management or multidisciplinary telemonitoring/telephone support program?
- What proportion have been referred to an exercise training program?
- What is the 30-day and 6-month mortality rate?
- What is the 30-day and 6-month rehospitalisation rate?

Abbreviations: ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; ECG = electrocardiogram; HF = heart failure; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist.

proportion of patients achieving target doses of their medications, which translates into clinical benefits including decreased rehospitalisation and improved survival.<sup>65</sup>

### Exercise training

Regular performance of up to moderate-intensity continuous exercise is recommended in patients with chronic HF, particularly in those with reduced LVEF, to improve quality of life and reduce hospitalisation for heart failure.<sup>66</sup>

### Comorbidities

Comorbidities are common in patients with HF, are associated with worse quality of life and health outcomes, and may interfere with standard HF management. A structured framework to identify and address comorbidities has been proposed.<sup>67</sup> A summary of the approach to managing comorbidities in patients with HF is provided in the Table.

### Palliative care

Palliative care services have been shown to alleviate end-stage symptoms, improve

quality of life and decrease rehospitalisation.<sup>68</sup> Referral to such services should be considered in patients with advanced HF, and should include discussions regarding 'ceiling of care' and deactivation of implantable cardioverter defibrillators. Patients with HF should be encouraged to have an advanced care plan.

### How to measure quality of care in heart failure

Better adherence to clinical guidelines is associated with better health outcomes. Ongoing audit and timely feedback should ideally be integrated into work practice to improve and maintain the quality of care. A list of suggested process and outcome quality measures is provided in Box 2.

### Conclusion

The HF guidelines are designed to facilitate the systematic integration of recommendations into the care of patients with HF. This includes ongoing audit and feedback systems integrated into work practices to improve the quality of care and outcomes of patients with HF. **MI**


### References

A list of references is included in the online version of this article ([www.medicinetoday.com.au](http://www.medicinetoday.com.au)).

COMPETING INTERESTS: Associate Professor Atherton has received personal fees and nonfinancial support from AstraZeneca, nonfinancial support from Bayer, and personal fees from Boehringer Ingelheim, Eli Lilly, Novartis, Otsuka and Vifor Pharma. Associate Professor Audehm has received personal fees from Novartis and AstraZeneca. Ms Connell: None.

### ONLINE CPD JOURNAL PROGRAM

**What is the single most useful investigation in patients with suspected heart failure?**



Review your knowledge of this topic and earn CPD points by taking part in **MedicineToday's** Online CPD Journal Program. **Log in to** [www.medicinetoday.com.au/cpd](http://www.medicinetoday.com.au/cpd)

© WILDPixel/ISTOCKPHOTO.COM

# Heart failure guidelines

## A concise summary for the GP

**JOHN J. ATHERTON** PhD, MB BS, FRACP, FCSANZ, FESC; **RALPH AUDEHM** MB BS, DipRACOG  
**CIA CONNELL** BPharm, MCLinPharm

### References

- Atherton JJ, Sindone A, De Pasquale CG, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018. *Med J Aust* 2018; 209: 363-369.
- Atherton JJ, Sindone A, De Pasquale CG, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. *Heart Lung Circ* 2018; 27: 1123-208.
- Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2163-2196.
- Chan YK, Tuttle C, Ball J, et al. Current and projected burden of heart failure in the Australian adult population: a substantive but still ill-defined major health issue. *BMC Health Serv Res* 2016; 16: 501.
- Woods JA, Katzenellenbogen JM, Davidson PM, Thompson SC. Heart failure among Indigenous Australians: a systematic review. *BMC Cardiovasc Disord* 2012; 12: 99.
- Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A, Investigators JCARE-GENERAL. Characteristics and outcomes of patients with heart failure in general practices and hospitals. *Circ J* 2007; 71: 449-454.
- Taylor CJ, Ryan R, Nichols L, Gale N, Hobbs FR, Marshall T. Survival following a diagnosis of heart failure in primary care. *Fam Pract* 2017; 34: 161-168.
- He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. *Arch Intern Med* 2001; 161: 996-1002.
- Goncalves A, Claggett B, Jhund PS, et al. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. *Eur Heart J* 2015; 36: 939-945.
- Dorans KS, Mostofsky E, Levitan EB, Hakansson N, Wolk A, Mittleman MA. Alcohol and incident heart failure among middle-aged and elderly men: cohort of Swedish men. *Circ Heart Fail* 2015; 8: 422-427.
- Larsson SC, Orsini N, Wolk A. Alcohol consumption and risk of heart failure: a dose-response meta-analysis of prospective studies. *Eur J Heart Fail* 2015; 17: 367-373.
- Pandey A, Garg S, Khunger M, et al. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. *Circulation* 2015; 132: 1786-1794.
- Aune D, Sen A, Norat T, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. *Circulation* 2016; 133: 639-649.
- Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet* 2016; 387: 957-67.
- Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. *Eur Heart J* 2015; 36: 1536-1546.
- Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. *Lancet* 2006; 368: 581-588.
- Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet* 2019; 393: 31-39.
- The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med* 1992; 327: 685-691.
- Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. *J Am Coll Cardiol* 1999; 33: 916-923.
- Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. *Arch Intern Med* 2004; 164: 1978-1984.
- Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. *Lancet* 2000; 355: 1575-1581.
- CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. *Lancet* 1999; 353: 9-13.
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999; 353: 2001-2007.
- Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001; 344: 1651-1658.

25. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005; 26: 215-225.
26. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999; 341: 709-717.
27. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011; 364: 11-21.
28. Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. *Eur J Heart Fail* 2018; 20: 1230-1239.
29. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. *Eur Heart J* 2018; 39: 26-35.
30. Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. *Eur Heart J* 2016; 37: 455-462.
31. Cardiovascular Expert Group. Therapeutic guidelines: cardiovascular. Version 7. Melbourne: Therapeutic Guidelines Limited; 2018.
32. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. *Cochrane Database Syst Rev* 2012(2): CD003838.
33. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014; 371: 993-1004.
34. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010; 376: 875-885.
35. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. *N Engl J Med* 1986; 314: 1547-1552.
36. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med* 1991; 325: 303-310.
37. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med* 2004; 351: 2049-2057.
38. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; 372:1223-30.
39. Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336: 525-533.
40. Hopper I, Samuel R, Hayward C, Tonkin A, Krum H. Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysis. *J Card Fail* 2014; 20: 522-532.
41. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. *Lancet* 2019; 393: 61-73.
42. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005; 352: 225-237.
43. Stavrakis S, Asad Z, Reynolds D. Implantable cardioverter defibrillators for primary prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. *J Cardiovasc Electrophysiol* 2017; 28: 659-665.
44. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. *Eur Heart J* 2013; 34: 3547-3556.
45. Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. *Heart* 2015; 101:1800-1806.
46. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. *N Engl J Med* 2016; 374: 1511-1520.
47. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017; 38: 2739-2791.
48. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010; 363: 1597-1607.
49. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011; 364: 2187-2198.
50. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014; 370: 1790-1798.
51. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 2016; 374: 1609-1620.
52. Deja MA, Grayburn PA, Sun B, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. *Circulation* 2012; 125: 2639-2648.
53. Obadia J-F, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. *N Engl J Med* 2018; 379: 2297-2306.
54. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med* 2018; 379: 2307-23018.
55. Mehra MR, Goldstein DJ, Uriel N, et al. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. *N Engl J Med* 2018; 378: 1386-1395.
56. Lund LH, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant* 2016; 35: 1158-1169.
57. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med* 2006; 355: 251-259.
58. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet* 2003; 362: 777-781.
59. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med* 2008; 359: 2456-2467.
60. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur Heart J* 2006; 27: 2338-2345.
61. Pitt B, Pfeffer MA, Assmann SF, Boineau R, et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med* 2014; 370: 1383-1392.
62. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. *J Am Coll Cardiol* 2004; 44: 810-819.
63. Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG. Structured telephone support or non-invasive telemonitoring for patients with heart failure. *Cochrane Database Syst Rev* 2015(10): CD007228.
64. Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. *Lancet* 2018; 392:1047-57.
65. Driscoll A, Currey J, Tonkin A, Krum H. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. *Cochrane Database Syst Rev* 2015(12): CD009889.
66. Sagar VA, Davies EJ, Briscoe S, et al. Exercise-based rehabilitation for heart failure: systematic review and meta-analysis. *Open Heart* 2015; 2: e000163.
67. Stewart S, Riegel B, Boyd C, et al. Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement. *Int J Cardiol* 2016; 212: 1-10.
68. Kavalieratos D, Corbelli J, Zhang D, et al. Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis. *JAMA* 2016; 316: 2104-2114.